Breakthroughs in prostate cancer screening and a ‘watch and wait’ treatment for collapsed lung share the Australian Clinical Trials Alliance 2021 Trial of the Year Award
The Australian Clinical Trials Alliance (ACTA) is pleased to announce dual winners of their preeminent 2021 ACTA Trial of the Year Award. This event celebrates the vital role trials have in advancing clinical practice and saving or improving patients’ lives every year. The dual winners of the 2021 Trial of the Year Award are:
- ProPSMA
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (ProPSMA): a prospective, randomised, multicentre study. - Pneumothorax study
A randomised controlled trial of conservative versus interventional treatment for spontaneous pneumothorax.
The ProPSMA clinical trial provides greater accuracy in identifying prostate cancer and the Pneumothorax clinical trial finds a ‘watch and wait’ approach is best to treat a collapsed lung. Full details of both winners can be found in the ACTA Media Release.
Other awards winners are as follows:
2021 ACTA Trial of the Year Award Finalist: PEPTIC
Effect of stress ulcer prophylaxis with proton pump inhibitors vs. Histamine-2 receptor blockers on inhospital mortality among ICU patients with invasive mechanical ventilation
2021 ACTA Trial of the Year Commendation: REMAP-CAP
Randomised, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia: Corticosteroid Domain
2021 Excellence in Trials Statistics Award Winner: PEPTIC
Effect of stress ulcer prophylaxis with proton pump inhibitors vs. Histamine-2 receptor blockers on inhospital mortality among ICU patients with invasive mechanical ventilation
2021 Excellence in Trials Statistics Commendation: REMAP-CAP
Randomised, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia: Corticosteroid Domain
2021 Consumer Involvement Commendation: CHIRI
Improving the control of hypertension in rural India: Overcoming barriers to diagnosis and effective treatment.
Next year ACTA will be adding the ‘Industry Partnership Award’ to their list of awards. Nominations open in January 2022.